H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $30 from $32 and keeps a Buy rating on the shares following the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Controversial Prasad leaving FDA, NYT reports
- RegenXbio Faces FDA Clinical Holds: Heightened Development Risk, Potential Delays, and Investor Uncertainty
- Buy These 3 Best Stocks Now, According to Top Wall Street Analysts, 3/6/2026
- RegenXBio Earnings Call Balances Gene Therapy Risks
- Regenxbio price target lowered to $17 from $18 at Morgan Stanley